In the rapidly evolving landscape of metabolic health, the demand for high-quality, reliable data in Type 2 Diabetes (T2DM) and obesity trials has never been greater. DelRicht Research has proven to be a cornerstone partner for T2DM and obesity clinical trials. By combining aggressive recruitment strategies with a streamlined operational model, DelRicht continues to set the standard for clinical excellence in the metabolic space.

Strategic Site Footprint and Investigator Expertise

DelRicht Research deployed a powerhouse network of six high-performing sites for this protocol, spanning key markets to ensure patient diversity and rapid enrollment. Our success is anchored by a roster of experienced Principal Investigators who specialize in the complexities of Type 2 Diabetes trials and weight management:

– Dr. Melita Tate | Tulsa, OK
– Dr. Olabisi Badmus | Charlotte, NC
– Dr. Robert Springer | Atlanta, GA
– Dr. Sean Kerby | Gulfport, MS
– Dr. Matthew Mintz | Rockville, MD
– Dr. Rachael Holliday | Indianapolis, IN

Operational Efficiency: Redefining Startup Timelines

DelRicht Research prides itself on a rapid-start infrastructure that minimizes the gap between award and activation. Our network demonstrated industry-leading agility with an average activation to screen time of just 7.7 days. Our Indianapolis site achieved a remarkable 1-day turnaround from activation to first patient screening, while our Atlanta site followed closely at just 2 days.

Our centralized regulatory team ensures that essential documents are turned around within 24 hours and CTA/Budget reviews are completed within 48 hours, resulting in rapid receipt-to-execution timelines.

Overcoming Key Challenges

A primary obstacle in this Phase 3 trial was the incretin-naïve recruitment hurdle, requiring participants to have no exposure to GLP-1 or SGLT-2 therapy medications now considered the global standard. This constraint, coupled with a mandatory dilated fundoscopy examination narrowed the available patient pool. DelRicht mitigated these bottlenecks by leveraging established referral networks to identify newly diagnosed or diet-controlled patients before they progressed to excluded therapies. This approach streamlined the enrollment workflow by integrating early-access fundoscopy pre-screening to bypass eligibility delays.

The study required navigating an intensive 8 month schedule involving weekly in-clinic subcutaneous injections. In double-blind obesity trials, the absence of open-label extensions often leads to high attrition, as the placebo effect can diminish participant motivation. To counter this, DelRicht employed patient education and engagement strategies: proactively managing placebo expectations through thorough patient education, ensuring high responsiveness, and implementing streamlined visit timelines to minimize participant burden.

What This Means for Sponsors and CROs

This study reinforces several key takeaways for sponsors and CROs navigating complex metabolic trials:

– Rapid start-up timelines can significantly accelerate overall study progress when paired with strong internal coordination
– Real-time eligibility strategies, such as point-of-care testing, help mitigate variability and reduce screen failures
– Leveraging existing patient databases enables more targeted recruitment and higher-quality enrollment
– Sites that combine operational rigor with proactive planning consistently outperform expectations

Our six participating sites exemplify how experienced sites can turn protocol complexity into a competitive advantage, delivering both speed and quality at scale.

Your Partner in Metabolic Innovation

DelRicht Research is purpose-built to handle the rigors of Phase 3 metabolic trials. By combining deep therapeutic expertise with a proven operational model that prioritizes both speed and data integrity, we help sponsors move medicine forward with confidence. Whether navigating complex exclusion criteria or managing long-term retention, DelRicht delivers the results your therapy deserves.